BioCentury
ARTICLE | Finance

Combo quest

Why NantKwest led Viracta’s B round

April 7, 2017 10:01 PM UTC

By leading Viracta Therapeutics Inc.’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal.

Wicklow Capital, Latterell Venture Partners and Forward Ventures joined NantKwest in the tranched $18.4 million series B round...

BCIQ Target Profiles

HDAC